Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses developing anti-fibrotic and anti-inflammatory therapies to treat cardiovascular disease. Its lead product is CardiolRx, which reduces cardiovascular and respiratory events in patients hospitalized with COVID-19. The company is also developing a subcutaneous formulation of CardiolRx to treat fibrosis and inflammation that progress to heart failure. Cardiol Therapeutics was incorporated in 2017 and is headquartered in Oakville, Ontario, Canada.
Name / Ticker | Price | Zen Rating |
---|---|---|
$30.12 | A | |
$3.07 | A | |
$8.25 | A |